NO985981L - Insulinpreparater som inneholder NaCl - Google Patents

Insulinpreparater som inneholder NaCl

Info

Publication number
NO985981L
NO985981L NO985981A NO985981A NO985981L NO 985981 L NO985981 L NO 985981L NO 985981 A NO985981 A NO 985981A NO 985981 A NO985981 A NO 985981A NO 985981 L NO985981 L NO 985981L
Authority
NO
Norway
Prior art keywords
insulin preparations
preparations containing
containing nacl
insulin
nacl
Prior art date
Application number
NO985981A
Other languages
English (en)
Other versions
NO985981D0 (no
NO324430B1 (no
Inventor
Elsebeth Norup
R Liselotte Langkj
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO985981(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO985981D0 publication Critical patent/NO985981D0/no
Publication of NO985981L publication Critical patent/NO985981L/no
Publication of NO324430B1 publication Critical patent/NO324430B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO19985981A 1996-06-20 1998-12-18 Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater. NO324430B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en) 1996-06-20 1997-06-19 INSULIN PREPARATIONS CONTAINING NaCl

Publications (3)

Publication Number Publication Date
NO985981D0 NO985981D0 (no) 1998-12-18
NO985981L true NO985981L (no) 1998-12-18
NO324430B1 NO324430B1 (no) 2007-10-15

Family

ID=8096378

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985981A NO324430B1 (no) 1996-06-20 1998-12-18 Vandige insulinpreparater som inneholder et halogenid, parenterale farmasoytiske preparater som omfatter slike insulinpreparater og fremgangsmate for forbedring av den kjemiske stabiliteten til slike insulinpreparater.

Country Status (21)

Country Link
EP (1) EP0921812B2 (no)
JP (2) JP4404380B2 (no)
KR (1) KR100451778B1 (no)
CN (1) CN1120019C (no)
AT (1) ATE208208T1 (no)
AU (1) AU720484B2 (no)
BR (1) BR9709845B1 (no)
CA (1) CA2258097C (no)
CZ (1) CZ297937B6 (no)
DE (1) DE69708121T3 (no)
DK (1) DK0921812T4 (no)
ES (1) ES2167751T5 (no)
HU (1) HU228094B1 (no)
IL (2) IL127366A0 (no)
NO (1) NO324430B1 (no)
PL (1) PL189964B1 (no)
PT (1) PT921812E (no)
RU (1) RU2182015C2 (no)
UA (1) UA49890C2 (no)
WO (1) WO1997048414A1 (no)
ZA (1) ZA975470B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE69914934T2 (de) * 1998-11-18 2005-01-05 Novo Nordisk A/S Stabile, wässrige insulin-präparate ohne phenol und cresol
JP2002535287A (ja) * 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
EP1165063A1 (en) * 1999-04-05 2002-01-02 Verteletsky, Pavel Vasilievich Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
PL355378A1 (en) * 1999-12-16 2004-04-19 Eli Lilly And Company Polypeptide compositions with improved stability
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2005291233B2 (en) 2004-10-05 2011-02-03 Novo Nordisk A/S A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104870469A (zh) * 2012-12-26 2015-08-26 沃克哈特有限公司 药物组合物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
CN114939156A (zh) * 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
AU6995794A (en) * 1993-06-21 1995-01-17 Novo Nordisk A/S Aspb28 insulin crystals
PL178466B1 (pl) * 1993-09-17 2000-05-31 Novo Nordisk As Pochodna insuliny i kompozycja farmaceutyczna do leczenia cukrzycy
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations

Also Published As

Publication number Publication date
NO985981D0 (no) 1998-12-18
EP0921812B2 (en) 2011-12-21
JP2000513344A (ja) 2000-10-10
NO324430B1 (no) 2007-10-15
DE69708121T3 (de) 2012-05-16
HUP9904031A2 (hu) 2000-04-28
IL127366A0 (en) 1999-10-28
IL127366A (en) 2007-07-04
ZA975470B (en) 1997-12-22
HUP9904031A3 (en) 2000-10-30
KR20000022031A (ko) 2000-04-25
DK0921812T3 (da) 2002-02-11
AU3253697A (en) 1998-01-07
ATE208208T1 (de) 2001-11-15
BR9709845A (pt) 1999-08-10
KR100451778B1 (ko) 2004-11-16
DE69708121D1 (de) 2001-12-13
JP2009235075A (ja) 2009-10-15
WO1997048414A1 (en) 1997-12-24
ES2167751T5 (es) 2012-03-30
AU720484B2 (en) 2000-06-01
JP4404380B2 (ja) 2010-01-27
BR9709845B1 (pt) 2008-11-18
HU228094B1 (en) 2012-10-29
CN1222083A (zh) 1999-07-07
CA2258097C (en) 2011-02-08
CZ395698A3 (cs) 1999-05-12
EP0921812A1 (en) 1999-06-16
PL330763A1 (en) 1999-05-24
DK0921812T4 (da) 2012-04-02
CA2258097A1 (en) 1997-12-24
EP0921812B1 (en) 2001-11-07
DE69708121T2 (de) 2002-08-01
CN1120019C (zh) 2003-09-03
CZ297937B6 (cs) 2007-05-02
ES2167751T3 (es) 2002-05-16
PT921812E (pt) 2002-04-29
RU2182015C2 (ru) 2002-05-10
PL189964B1 (pl) 2005-10-31
UA49890C2 (uk) 2002-10-15

Similar Documents

Publication Publication Date Title
NO985981D0 (no) Insulinpreparater som inneholder NaCl
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
PT758248E (pt) Formulacoes para o factor ix
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
ID24520A (id) Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya
ATE231872T1 (de) Thiazolopyrimidinderivate
NO995831D0 (no) Injiserbar, klar formulering av et anestetisk middel
ES2071663T3 (es) Analogo de fluoxetina.
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
ES2152315T3 (es) Xamoneline tartrato.
ATE196914T1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
EP0270841A3 (de) 2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ATE145824T1 (de) Aerosolformulierung enthaltend fusafungin
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
FR2707492B1 (fr) Nouvelles compositions cosmétiques ou dermatologiques renfermant les ribosomes, préparation des ribosomes, préparation desdites compositions et leur application.
ES2051916T3 (es) Procedimiento para la obtencion de formiltrimetilbiciclo(2.2.2)oct-7-enos isomeros.
NO903705D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n-disubstituerte arylcykloalkylaminer.
ES1006401Y (es) Pata niveladora, para muebles y similares.
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.
ATE82855T1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosidphosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.

Legal Events

Date Code Title Description
MK1K Patent expired